CONSUN PHARMAC.GR.HD -10 (C1P) - Net Assets
Based on the latest financial reports, CONSUN PHARMAC.GR.HD -10 (C1P) has net assets worth €4.65 Billion EUR (≈ $5.43 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€6.09 Billion ≈ $7.12 Billion USD) and total liabilities (€1.45 Billion ≈ $1.69 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CONSUN PHARMAC.GR.HD -10 liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.65 Billion |
| % of Total Assets | 76.26% |
| Annual Growth Rate | 14.7% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2.53 |
CONSUN PHARMAC.GR.HD -10 - Net Assets Trend (2021–2024)
This chart illustrates how CONSUN PHARMAC.GR.HD -10's net assets have evolved over time, based on quarterly financial data. Also explore CONSUN PHARMAC.GR.HD -10 total assets for the complete picture of this company's asset base.
Annual Net Assets for CONSUN PHARMAC.GR.HD -10 (2021–2024)
The table below shows the annual net assets of CONSUN PHARMAC.GR.HD -10 from 2021 to 2024. For live valuation and market cap data, see CONSUN PHARMAC.GR.HD -10 market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €4.39 Billion ≈ $5.14 Billion |
+12.10% |
| 2023-12-31 | €3.92 Billion ≈ $4.58 Billion |
+13.95% |
| 2022-12-31 | €3.44 Billion ≈ $4.02 Billion |
+18.15% |
| 2021-12-31 | €2.91 Billion ≈ $3.40 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CONSUN PHARMAC.GR.HD -10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 57.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €3.41 Billion | 83.12% |
| Other Components | €691.49 Million | 16.88% |
| Total Equity | €4.10 Billion | 100.00% |
CONSUN PHARMAC.GR.HD -10 Competitors by Market Cap
The table below lists competitors of CONSUN PHARMAC.GR.HD -10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Realia
MC:RLIA
|
$1.57 Billion |
|
Yinson Holdings Bhd
KLSE:7293
|
$1.57 Billion |
|
Ahlatci Dogal Gaz Dagitim Enerji ve Yatirim A.S.
IS:AHGAZ
|
$1.57 Billion |
|
Vir Biotechnology Inc
NASDAQ:VIR
|
$1.57 Billion |
|
Astrana Health Inc
NASDAQ:ASTH
|
$1.57 Billion |
|
Ellington Financial Inc.
NYSE:EFC
|
$1.57 Billion |
|
China National Electric Apparatus R
SHG:688128
|
$1.57 Billion |
|
ELECTROLUX B ADR/2 SK 5
F:ELXA
|
$1.57 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CONSUN PHARMAC.GR.HD -10's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,626,503,000 to 4,097,603,000, a change of 471,100,000 (13.0%).
- Net income of 910,458,000 contributed positively to equity growth.
- Dividend payments of 680,544,000 reduced retained earnings.
- New share issuances of 240,496,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €910.46 Million | +22.22% |
| Dividends Paid | €680.54 Million | -16.61% |
| Share Issuances | €240.50 Million | +5.87% |
| Other Changes | €690.00K | +0.02% |
| Total Change | €- | 12.99% |
Book Value vs Market Value Analysis
This analysis compares CONSUN PHARMAC.GR.HD -10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.35x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.54x to 0.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.18 | €1.70 | x |
| 2022-12-31 | €3.90 | €1.70 | x |
| 2023-12-31 | €4.58 | €1.70 | x |
| 2024-12-31 | €4.82 | €1.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CONSUN PHARMAC.GR.HD -10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 22.22%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 30.68%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.43x
- Recent ROE (22.22%) is above the historical average (22.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 22.55% | 28.86% | 0.47x | 1.67x | €328.40 Million |
| 2022 | 21.71% | 29.19% | 0.48x | 1.56x | €368.39 Million |
| 2023 | 21.63% | 30.29% | 0.47x | 1.52x | €421.88 Million |
| 2024 | 22.22% | 30.68% | 0.51x | 1.43x | €500.70 Million |
Industry Comparison
This section compares CONSUN PHARMAC.GR.HD -10's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $778,651,241
- Average return on equity (ROE) among peers: -82.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CONSUN PHARMAC.GR.HD -10 (C1P) | €4.65 Billion | 22.55% | 0.31x | $1.57 Billion |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $6.51 Billion | 11.81% | 0.39x | $635.99 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $113.81K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| EQL PHARMA AB (7JK) | $154.75 Million | 19.98% | 0.85x | $148.83 Million |
| Alkermes plc (8AK) | $1.07 Billion | 1.94% | 0.48x | $5.00 Billion |
| OPTIMI HEALTH CORP. (8BN) | $9.58 Million | -63.03% | 0.52x | $17.99 Million |
| LABIANA HEALTH S.A.EO-10 (8RK) | $2.57 Million | 9.87% | 19.25x | $40.60 Million |
| CANNABIS POLAND AB ZY-10 (8TE) | $3.54 Million | -57.78% | 0.18x | $1.75 Million |
| Apontis Pharma AG (APPH) | $40.71 Million | -1.83% | 0.33x | $91.63 Million |
| CRAFTPORT CANNABIS CORP. (BBW0) | $-3.18 Million | 0.00% | 0.00x | $1.45 Million |
About CONSUN PHARMAC.GR.HD -10
Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney… Read more